Hear what the media is saying about Vistagen Therapeutics, and the products we are developing to exceed the current standard of care.
May 24, 2023
Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health Awareness Month and MHA’s nationwide efforts to fight stigma and provide support around mental health SOUTH
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
Apr 19, 2023
Results from new study further support that fasedienol acts locally in the nasal passages and does not require systemic uptake or direct activity on neurons in the brain to achieve fast-acting anti-anxiety effects SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr.
Apr 06, 2023
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
Mar 30, 2023
Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety disorder (SAD) FDA provides helpful guidance on key aspects of potential NDA-enabling development plan in